HUTCHMED (HCM) closed the last trading session at $15.30, gaining 4.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.75 indicates a 68.3% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $9.71. While the lowest estimate of $18 indicates a 17.7% increase from the current price level, the most optimistic analyst expects the ...

PAR Technology (PAR) closed the last trading session at $65.46, gaining 6.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $87.38 indicates a 33.5% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $10.27. While the lowest estimate of $65 indicates a 0.7% decline from the current price level, the most optimistic analyst expec ...

Group 1 - BioLife Solutions, Inc. (BLFS) closed at $22.03, with a 3.2% gain over the past four weeks, and a mean price target of $31.22 indicating a 41.7% upside potential [1] - The average of nine short-term price targets ranges from $30 to $34, with a standard deviation of $1.48, suggesting a low variability among analysts [2] - Analysts are optimistic about BLFS's earnings prospects, with a significant increase in the Zacks Consensus Estimate for the current year by 123.1% [12] Group 2 - The Zacks Rank for BLFS is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - Analysts' agreement on higher earnings estimates is a strong indicator of potential stock price movements, as empirical research shows a correlation between earnings estimate revisions and stock price changes [11] - While price targets are often viewed skeptically, the direction they imply for BLFS appears to be a good guide for potential upside [10][13]

Benitec Biopharma Limited (BNTC) closed the last trading session at $15.49, gaining 14.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.71 indicates a 66% upside potential.The average comprises seven short-term price targets ranging from a low of $17 to a high of $35, with a standard deviation of $6.70. While the lowest estimate indicates an increase of 9.8% from the current ...

Knightscope, Inc. (KSCP) closed the last trading session at $6.06, gaining 25.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17 indicates an 180.5% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $11.36. While the lowest estimate of $9 indicates a 48.5% increase from the current price level, the most optimistic analyst e ...

FTAI Aviation (FTAI) closed the last trading session at $123.35, gaining 14.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $171 indicates a 38.6% upside potential.The average comprises 12 short-term price targets ranging from a low of $123 to a high of $300, with a standard deviation of $46.90. While the lowest estimate indicates a decline of 0.3% from the current price level, ...

Rambus (RMBS) closed the last trading session at $56.30, gaining 12.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.25 indicates a 28.3% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $9.97. While the lowest estimate of $55 indicates a 2.3% decline from the current price level, the most optimistic analyst expects the ...

Core Viewpoint - Zymeworks Inc. (ZYME) shows potential for significant upside, with a mean price target of $21.35 indicating a 76.7% increase from its current price of $12.08 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $7.45, indicating variability among analysts [2] - The lowest estimate is $12, suggesting a slight decline of 0.7%, while the highest estimate predicts a surge of 148.3% to $30 [2] - Analysts' price targets are often questioned for their reliability, as they may mislead investors rather than provide accurate guidance [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about ZYME's earnings, with a consensus indicating better-than-previously estimated earnings [4] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with four estimates increasing and no negative revisions [12] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, suggesting potential upside for ZYME [11] Zacks Rank and Investment Potential - ZYME holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [13]

Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) closed the last trading session at $13.36, gaining 11.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.90 indicates a 138.8% upside potential.The average comprises 10 short-term price targets ranging from a low of $27 to a high of $38, with a standard deviation of $4.01. While the lowest estimate indicates an increase of 102.1 ...

Shares of Spire Global, Inc. (SPIR) have gained 7.2% over the past four weeks to close the last trading session at $10.38, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $16.60 indicates a potential upside of 59.9%.The average comprises five short-term price targets ranging from a low of $13 to a high of $20, with a standard deviation of $2.51. While the lowest estimate indicat ...